Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Open accessThe DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The interrogation of proteomes ("proteomics") in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine. METHODOLOGY/PRINCIPAL FINDINGS: We present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 µL of serum or plasma). Our current assay measures 813 proteins with low limits of detection (1 pM median), 7 logs of overall dynamic range (~100 fM-1 µM), and 5% median coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding signature of DNA aptamer concentrations, which is quantified on a DNA microarray. Our assay takes advantage of the dual nature of aptamers as both folded protein-binding entities with defined shapes and unique nucleotide sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to rapidly discover unique protein signatures characteristic of various disease states. CONCLUSIONS/SIGNIFICANCE: We describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major developments in mass spectrometry-based, antibody-based and aptamer-based proteomics over the past decade have enabled the robust quantification of thousands of proteins in single samples87–90.”
From Measuring biological age using omics data (2022) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The assay uses DNA-based slow off-rate modified aptamers (SOMAmerTM reagents) to quantify the relative abundance of approximately 7000 proteins with high specificity and limits of detection largely comparable to antibody-based assays.”
From Cross-ancestry comparison of aptamer and antibody protein measures (2026) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Proteomic technologies, including mass spectrometry–based proteomics, aptamer-based arrays (SomaLogic), and proximity extension assay technology (Olink), are now available for the large-scale quantification and validation of thousands of proteins in human biological fluids or tissues (122–127).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RNA-Mediated Metal-Metal Bond Formation in the Synthesis of Hexagonal Palladium Nanoparticles
Gugliotti, L. A., Feldheim, D. L., & Eaton, B. E. (2004) · Science · doi:10.1126/science.1095678 · Cited by 197 · cited 2×
“This innovation was used to select catalysts, including the first RNA-catalyzed carbon-carbon bond formation [16,23].”
MethodSelf-citationRetractedLevey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405 · cited 4×
“Based on the collective knowledge of the aptamer field that has developed since its inception [13,14], we hypothesized that aptamers could make exceptional reagents for high-content proteomics.”
BackgroundInfluentialSelf-citationIn vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812 · cited 4×
“Based on the collective knowledge of the aptamer field that has developed since its inception [13,14], we hypothesized that aptamers could make exceptional reagents for high-content proteomics.”
BackgroundInfluentialKeller, A., Nesvizhskii, A. I., Kolker, E., & Aebersold, R. (2002) · Analytical Chemistry · doi:10.1021/ac025747h · Cited by 4,830 · cited 2×
“0% probability as specified by the Peptide Prophet algorithm [45].”
MethodA Statistical Model for Identifying Proteins by Tandem Mass Spectrometry
Nesvizhskii, A. I., Keller, A., Kolker, E., & Aebersold, R. (2003) · Analytical Chemistry · doi:10.1021/ac0341261 · Cited by 4,809 · cited 3×
“Protein probabilities were assigned by the Protein Prophet algorithm [44].”
MethodAssessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 2×
“Eleven subjects had early-stage CKD based on estimated GFR (Table 3) (eGFR, defined as stages 1–2, median creatinine clearance 70 ml/min/m, range 62–97 ml/min/m) and 31 had late-stage CKD (stages 3–5, median creatinine clearance 25 ml/min/m, range 7–49 ml/min/m) [33].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 1×
“Aptamers are a class of nucleic acid-based molecules discovered twenty years ago [13,14] and have since been employed in diverse applications including therapeutics [15], catalysis [16], and now proteomics.”
BackgroundHopfield, J. J. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.10.4135 · Cited by 1,594 · cited 2×
“Inspired by classic kinetic theory of specific binding in complex mixtures [25,26], we employed kinetic manipulations to help overcome the problem of non-specific SOMAmer-protein binding.”
MethodLevey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516 · cited 4×
“CKD biomarkers could also be useful for monitoring disease progression and guiding treatment [28–31].”
BackgroundInfluentialHigh-Resolution Molecular Discrimination by RNA
Jenison, R. D., Gill, S. C., Pardi, A., & Polisky, B. (1994) · Science · doi:10.1126/science.7510417 · Cited by 1,188 · cited 2×
“We believe that SOMAmers will be highly specific, given our previous experience with highly-specific aptamers including, for example, the drug Pegaptanib (Macugen) for the treatment age-related macular degeneration, which binds specifically to VEGF121 but not VEGF165 [37,38], and an aptamer that distinguishes theophyl…”
BackgroundAddona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1546 · Cited by 1,037
Functional Aptamers and Aptazymes in Biotechnology, Diagnostics, and Therapy
Famulok, M., Hartig, J. S., & Mayer, G. (2007) · Chemical Reviews · doi:10.1021/cr0306743 · Cited by 887 · cited 2×
“Aptamers are short single-stranded oligonucleotides, which fold into diverse and intricate molecular structures that bind with high affinity and specificity to proteins, peptides, and small molecules [17–19].”
BackgroundKinetic amplification of enzyme discrimination
Ninio, J. (1975) · Biochimie · doi:10.1016/s0300-9084(75)80139-8 · Cited by 758 · cited 2×
“Inspired by classic kinetic theory of specific binding in complex mixtures [25,26], we employed kinetic manipulations to help overcome the problem of non-specific SOMAmer-protein binding.”
MethodRuckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Self-citationEngineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
Multiplexed protein profiling on microarrays by rolling-circle amplification
Schweitzer, B., Roberts, S., Grimwade, B., Shao, W., Wang, M., Fu, Q., Shu, Q., Laroche, I., Zhou, Z., Tchernev, V. T., et al. (2002) · Nature Biotechnology · doi:10.1038/nbt0402-359 · Cited by 573 · cited 2×
“Although broadly used in single-analyte tests, it has recently become clear that such assays cannot be multiplexed above a few tens of simultaneous measurements [10,11] in large part because cross-reactivity of secondary antibodies to surface-immobilized proteins (including primary antibodies) dramatically erodes spec…”
BackgroundA method for reducing the time required to match protein sequences with tandem mass spectra
Craig, R., & Beavis, R. C. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1198 · Cited by 504 · cited 2×
“eGFR (median) 1 70 [62–97] 25 [7–49]”
MethodAptamers as therapeutic and diagnostic agents
Brody, E. N., & Gold, L. (2000) · Reviews in Molecular Biotechnology · doi:10.1016/s1389-0352(99)00004-5 · Cited by 494 · cited 2×
“Aptamers are short single-stranded oligonucleotides, which fold into diverse and intricate molecular structures that bind with high affinity and specificity to proteins, peptides, and small molecules [17–19].”
BackgroundSelf-citationVenturoli, D., & Rippe, B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00171.2004 · Cited by 461 · cited 2×
“We chose CKD as a test case because kidney physiology provides filtration of serum molecules based on size (molecular mass) and charge [32] – thus CKD might lead to an increase in the concentration of small proteins (MW ,45 kDa).”
MethodMass Spectrometry Based Targeted Protein Quantification: Methods and Applications
Pan, S., Aebersold, R., Chen, R., Rush, J., Goodlett, D. R., McIntosh, M. W., Zhang, J., & Brentnall, T. A. (2009) · Journal of Proteome Research · doi:10.1021/pr800538n · Cited by 396 · cited 2×
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
BackgroundRNA-catalysed carbon–carbon bond formation
Tarasow, T. M., Tarasow, S. L., & Eaton, B. E. (1997) · Nature · doi:10.1038/37950 · Cited by 368 · cited 3×
“Aptamers are a class of nucleic acid-based molecules discovered twenty years ago [13,14] and have since been employed in diverse applications including therapeutics [15], catalysis [16], and now proteomics.”
BackgroundMethodSelf-citationA HUPO test sample study reveals common problems in mass spectrometry–based proteomics
HUPO Test Sample Working Group, Bell, A. W., Deutsch, E. W., Au, C. E., Kearney, R. E., Beavis, R., Sechi, S., Nilsson, T., & Bergeron, J. J. M. (2009) · Nature Methods · doi:10.1038/nmeth.1333 · Cited by 351 · cited 2×
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
BackgroundExpanding the Chemistry of DNA for in Vitro Selection
Vaught, J. D., Bock, C., Carter, J., Fitzwater, T., Otis, M., Schneider, D., Rolando, J., Waugh, S., Wilcox, S. K., & Eaton, B. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908035g · Cited by 313 · cited 4×
“Building on this work, we developed modified deoxyribonucleotides and SELEX methods [24] to select modified DNA aptamers from libraries that incorporate one of four dUTPs modified at the 5-position (Figure 1).”
BackgroundMethodInfluentialSelf-citationOligonucleotides as Research, Diagnostic, and Therapeutic Agents
Gold, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.23.13581 · Cited by 266 · cited 3×
“There were many examples of high affinity RNA and DNA aptamers selected against human proteins [19].”
BackgroundSelf-citationOstroff, R., Bigbee, W., Franklin, W., Gold, L., Mehan, M., Miller, Y., Pass, H., Rom, W., Siegfried, J., Stewart, A., et al. (2010) · Nature Precedings · doi:10.1038/npre.2010.4537.1 · Cited by 213
Self-citationBiomarkers in acute and chronic kidney disease
Nickolas, T. L., Barasch, J., & Devarajan, P. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f4e525 · Cited by 200
Multiplexed protein detection by proximity ligation for cancer biomarker validation
Fredriksson, S., Dixon, W., Ji, H., Koong, A. C., Mindrinos, M., & Davis, R. W. (2007) · Nature Methods · doi:10.1038/nmeth1020 · Cited by 196 · cited 3×
“A recently reported proximity ligation assay that relies on antibody sandwich formation in solution followed by ligation of antibody-tethered nucleic acids and PCR amplification has been multiplexed with six analytes [10].”
BackgroundMetabolism of complement factor D in renal failure
Pascual, M. A., Steiger, G., Estreicher, J., Macon, K. J., Volanakis, J. E., & Schifferli, J. A. (1988) · Kidney International · doi:10.1038/ki.1988.214 · Cited by 128 · cited 2×
“Two of the eleven proteins, cystatin C and b2-microglobulin, are important known biomarkers of CKD [29–31] and two additional proteins, complement factor D and TNF sR-I, have been reported to have elevated concentrations in CKD [34,35].”
BackgroundThe joys of in vitro selection: chemically dressing oligonucleotides to satiate protein targets
Eaton, B. E. (1997) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(97)80103-2 · Cited by 123 · cited 3×
“Eaton and colleagues developed the technology to efficiently synthesize nucleotides modified with diverse functional groups and to utilize them in SELEX [21,22].”
BackgroundSelf-citationHigh-throughput proteomics using antibody microarrays: an update
Borrebaeck, C. A. K., & Wingren, C. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.5.673 · Cited by 123 · cited 2×
“This inherent characteristic compromises the performance of antibody-based arrays including printed antibodies, sandwich formats, and beadbased arrays [1,12].”
BackgroundBiomarker discovery and clinical proteomics
Silberring, J., & Ciborowski, P. (2010) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2009.11.007 · Cited by 101 · cited 1×
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
BackgroundPegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration
Doggrell, S. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.8.1421 · Cited by 90 · cited 2×
“We believe that SOMAmers will be highly specific, given our previous experience with highly-specific aptamers including, for example, the drug Pegaptanib (Macugen) for the treatment age-related macular degeneration, which binds specifically to VEGF121 but not VEGF165 [37,38], and an aptamer that distinguishes theophyl…”
BackgroundMitchell, P. J. (2010) · Nature Biotechnology · doi:10.1038/nbt0710-665 · Cited by 90
Proteomics and diagnostics: Let's Get Specific, again
Zichi, D., Eaton, B. E., Singer, B. S., & Gold, L. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.01.016 · Cited by 82
Self-citationGiannelli, S. V., Patel, K. V., Windham, B. G., Pizzarelli, F., Ferrucci, L., & Guralnik, J. M. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01196.x · Cited by 77 · cited 4×
“CKD biomarkers could also be useful for monitoring disease progression and guiding treatment [28–31].”
BackgroundInfluentialNew Uridine Derivatives for Systematic Evolution of RNA Ligands by Exponential Enrichment
Dewey, T. M., Mundt, A., Crouch, G. J., Zyzniewski, M. C., & Eaton, B. E. (1995) · Journal of the American Chemical Society · doi:10.1021/ja00137a027 · Cited by 76 · cited 2×
“Eaton and colleagues developed the technology to efficiently synthesize nucleotides modified with diverse functional groups and to utilize them in SELEX [21,22].”
BackgroundSelf-citationT7 RNA Polymerase Transcription with 5-Position Modified UTP Derivatives
Vaught, J. D., Dewey, T. M., & Eaton, B. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja049009h · Cited by 69
Self-citationVanholder, R. C., Laecke, S. V., & Glorieux, G. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.2.146 · Cited by 67 · cited 2×
“The accumulation of some (but not all) low molecular weight proteins, sometimes called ‘‘middle molecules’’, in plasma of patients with impaired renal filtration has long been implicated in the pathology of kidney disease[36].”
BackgroundService, R. F. (2008) · Science · doi:10.1126/science.321.5897.1758 · Cited by 63
A stress test for mass spectrometry–based proteomics
Aebersold, R. H. (2009) · Nature Methods · doi:10.1038/nmeth.f.255 · Cited by 61 · cited 2×
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
BackgroundThe Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease
Chaudhary, K. R., Phadke, G. M., Nistala, R., Weidmeyer, C. E., McFarlane, S. I., & Whaley‐Connell, A. T. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0080-z · Cited by 45 · cited 4×
“CKD biomarkers could also be useful for monitoring disease progression and guiding treatment [28–31].”
BackgroundInfluentialOverbeeke, I. C. V. R.-V., Baan, C. C., Hesse, C. J., Loonen, E. H. M., Niesters, H. G. M., Zietse, R., & Weimar, W. (2000) · PubMed · Cited by 44
Liotta, L. A., & Petricoin, E. F. (2010) · Clinical Proteomics · doi:10.1007/s12014-010-9045-0 · Cited by 8 · cited 1×
“Despite great promise for MS in clinical proteomics, many challenges remain including issues of sensitivity (typically nM in current approaches), specificity, reproducibility, throughput, and cost [2–9].”
Background
Cited by
Genomic atlas of the human plasma proteome
Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., Burgess, S., Jiang, T., Paige, E., Surendran, P., et al. (2018) · Nature · doi:10.1038/s41586-018-0175-2 · Cited by 2,268
Self-citationAptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Undulating changes in human plasma proteome profiles across the lifespan
Lehallier, B., Gate, D., Schaum, N., Nanasi, T., Lee, S. E., Yousef, H., Moran Losada, P., Berdnik, D., Keller, A., Verghese, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0673-2 · Cited by 981
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948
“The SOMAmer quantity is measured by hybridization to microarrays (for a full description, see Gold et al., 2010).”
Self-citation
Metadata
- Authors
- Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., Flather, D., Forbes, A., Foreman, T., Fowler, C., Gawande, B., Goss, M., Gunn, M., Gupta, S., Halladay, D., Heil, J., Heilig, J., Hicke, B., Husar, G., Janjic, N., Jarvis, T., Jennings, S., Katilius, E., Keeney, T. R., Kim, N., Koch, T. H., Kraemer, S., Kroiss, L., Le, N., Levine, D., Lindsey, W., Lollo, B., Mayfield, W., Mehan, M., Mehler, R., Nelson, S. K., Nelson, M., Nieuwlandt, D., Nikrad, M., Ochsner, U., Ostroff, R. M., Otis, M., Parker, T., Pietrasiewicz, S., Resnicow, D. I., Rohloff, J., Sanders, G., Sattin, S., Schneider, D., Singer, B., Stanton, M., Sterkel, A., Stewart, A., Stratford, S., Vaught, J. D., Vrkljan, M., Walker, J. J., Watrobka, M., Waugh, S., Weiss, A., Wilcox, S. K., Wolfson, A., Wolk, S. K., Zhang, C., & Zichi, D.
- Affiliations
- University of Colorado Boulder (US)
- SomaLogic (United States) (US)
- Cornell University (US)
- Corresponding author
- Gold, Larry
- Walker, Jeffrey J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-07
- Volume
- 5
- Issue
- 12
- Pages
- e15004
- ISSN
- 1756-0357 (ISSN-L)
- 1932-6203
- PMC
- PMC3000457
- OpenAlex
- W2084373725
- Cited by
- 1,754
- References
- 46
- Citations by year
- 2026: 164 · 2025: 190 · 2024: 170 · 2023: 154 · 2022: 184 · 2021: 127 · 2020: 115 · 2019: 105 · 2018: 95 · 2017: 98 · 2016: 78 · 2015: 73 · 2014: 60 · 2013: 56 · 2012: 50
- Type
- posted content
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Nature Precedings (publishedVersion, cc-by)
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Nature Precedings (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- aptamer-based proteomics, biomarker discovery, chemically modified nucleotides, DNA microarrays, plasma protein profiling, chronic kidney disease, multiplexed protein quantification, aptamer selection, disease biomarkers
- MeSH terms
- Aged, Female, Genetic Techniques, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Kinetics, Male, Middle Aged, Nucleic Acid Hybridization, Mass Spectrometry, Reproducibility of Results, Biomarkers, Gene Library, Evidence-Based Medicine, Oligonucleotide Array Sequence Analysis, Proteome, Proteomics, Aptamers, Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.